Compare Gilead Sciences, Inc. (GILD) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Quanta Services Inc — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Quanta Services Inc trades at $627.65 (market cap $97.37B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PWR | |
|---|---|---|
Market Cap | $163.51B | $97.37B |
Sector | Health | Industrials |
52-Week High | $155.80 | $785.24 |
52-Week Low | $108.22 | $372.50 |
Enterprise Value | $178.05B | $103.32B |
Dividend Yield | 2.49% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quanta Services (PWR) trades at $628.29, down 4.94% over 24 hours, with a bearish technical signal despite strong analyst support. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $28.48B in 2025, though net margins remain slim at 3.67%. The stock carries high valuation multiples, including a P/E of 89, reflecting investor optimism around infrastructure spending and AI-driven demand.
PWR's long-term outlook is supported by a record $48B backlog and exposure to grid modernization and data center expansion, but high valuation and aggressive capital expenditure pose risks. Analyst consensus is strongly bullish with a $836.80 price target, though near-term volatility may persist amid technical weakness and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
